We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

135 hedge funds and large institutions have $886M invested in Cogent Biosciences in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

242% more call options, than puts

Call options by funds: $940K | Put options by funds: $275K

61% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 36

20.62% more ownership

Funds ownership: 85.69% → 106.31% (+21%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

1% less funds holding

Funds holding: 136 → 135 (-1)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

15% less capital invested

Capital invested by funds: $1.05B → $886M (-$162M)

Holders
135
Holders Change
-1
Holders Change %
-0.74%
% of All Funds
2.14%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
12
Increased
58
Reduced
36
Closed
13
Calls
$940K
Puts
$275K
Net Calls
+$665K
Net Calls Change
+$444K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$50.4M
2
SCM
Suvretta Capital Management
New York
+$9.89M
3
BlackRock
BlackRock
New York
+$7.94M
4
SVCM
Saturn V Capital Management
Texas
+$7.5M
5
KCM
Kynam Capital Management
New Jersey
+$7.03M

Top Sellers

1
DM
Deerfield Management
New York
-$27M
2
EAM
Eventide Asset Management
Massachusetts
-$15.3M
3
FCM
Farallon Capital Management
California
-$11.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.9M
5
LGM
Logos Global Management
California
-$9.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
26
Cormorant Asset Management
Massachusetts
$9.75M – – –
5VM
27
5AM Venture Management
California
$7.71M – – –
CS
28
Candriam SCA
Luxembourg
$7.53M +$59.3K +5,000 +0.6%
Northern Trust
29
Northern Trust
Illinois
$6.95M +$1.17M +98,532 +16%
SCM
30
Silverarc Capital Management
Massachusetts
$6.35M +$372K +31,372 +5%
GTC
31
Ghost Tree Capital
New York
$6.34M +$890K +75,000 +13%
Assenagon Asset Management
32
Assenagon Asset Management
Luxembourg
$5.94M -$1.06M -89,373 -13%
Charles Schwab
33
Charles Schwab
California
$5.78M +$4.72M +397,765 +204%
NCM
34
Nantahala Capital Management
Connecticut
$5.61M +$6.06M +510,868 +797%
Walleye Capital
35
Walleye Capital
New York
$5.39M -$526K -44,318 -7%
BC
36
Boxer Capital
California
$5.12M – – –
NLVP
37
New Leaf Venture Partners
New York
$4.89M – – –
PIM
38
Platinum Investment Management
Australia
$4.64M -$14.7K -1,243 -0.3%
SFM
39
Sphera Funds Management
Israel
$4.09M – – –
Goldman Sachs
40
Goldman Sachs
New York
$3.9M +$416K +35,048 +10%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$2.81M +$468K +39,491 +16%
JP Morgan Chase
42
JP Morgan Chase
New York
$2.62M +$23.2K +1,953 +0.7%
KCM
43
Kennedy Capital Management
Missouri
$2.6M -$6.2K -523 -0.2%
SSA
44
Schonfeld Strategic Advisors
New York
$2.32M +$472K +39,805 +20%
ACM
45
Altium Capital Management
New York
$2.29M – – –
Macquarie Group
46
Macquarie Group
Australia
$2.24M – – –
Connor, Clark & Lunn Investment Management (CC&L)
47
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.2M -$595K -50,194 -18%
PBA
48
Paradigm Biocapital Advisors
New York
$2.2M +$2.68M +225,605 New
N
49
Nuveen
North Carolina
$2.16M -$386K -32,551 -13%
HS
50
HighVista Strategies
Massachusetts
$1.94M -$208K -17,543 -8%
1
2
3 4 5

COGT Hedge Fund Activity: Q3 2023 in Review

135 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2023, worth a combined $886M — down 15% from $1.05B a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of COGT and 12 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 58 added.

The largest buyer was Fidelity Investments, adding an estimated $50.4M. The largest seller was Deerfield Management, cutting an estimated $27M.

  • 135 institutional investors held Cogent Biosciences (COGT) as of Q3 2023, down from 136 in Q2 2023.
  • Funds reported $886M of Cogent Biosciences stock for Q3 2023, down 15% quarter-over-quarter.
  • 12 funds opened new Cogent Biosciences positions in Q3 2023 and 13 closed out, a net change of -1 holder.
  • The largest Cogent Biosciences buyer in Q3 2023 was Fidelity Investments, an estimated $50.4M added.
  • The largest Cogent Biosciences seller in Q3 2023 was Deerfield Management, an estimated $27M sold.

Based on aggregated 13F filings for Q3 2023.